The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

Autor Maetzel, A. Google Scholar
Ferraz, M. B. Google Scholar
Bombardier, C. Google Scholar
Instituição Wellesley Hosp
Universidade Federal de São Paulo (UNIFESP)
Univ Toronto
Resumo Objective. To reexamine the cost-effectiveness of misoprostol, using data from a recently published placebo-controlled trial of misoprostol in >8,000 patients with rheumatoid arthritis (RA) taking nonsteroidal antiinflammatory drugs (the Misoprostol Ulcer Complications Outcome Safety Assessment [MUCOSA] study).Methods. Actual clinical events and the rates of endoscopies and upper gastrointestinal (GI) radiographic series, hospitalizations, and surgery for these events were derived from the MUCOSA study and used in a decision analysis. Estimates of costs for the management of these events were derived from the Ontario Case Cost Project database and published economic evaluations; cases were adjusted to 1994 Canadian dollars. Incremental cost-effectiveness (from the viewpoint of the provincial health care plan in Canada) was calculated for the original trial population (risk of a serious GI complication 1%) and for the subsets of patients with medium (3%) and high (6%) risk.Results. for the original study population, averting 1 serious GI complication by prescribing misoprostol would cost an additional $94,766 (Canadian; range $60,266-137,146). for patients with previous peptic ulcer disease (medium risk), the cost would be $14,943 (range $10,912-32,157), and for patients with previous peptic ulcer disease and age >75 (high risk), the cost would be $4,101 (range $-220 to $18,146).Conclusion. Prescribing misoprostol for all patients with RA who are greater than or equal to 52 years old costs $94,766 for each additional GI event averted. However, when patients at higher risk are specifically selected, the cost per averted GI complication is markedly reduced. These results, based on actual serious event rates and actual data on endoscopies and upper GI series, hospitalizations, and surgeries, provide a better estimate of the true cost-effectiveness of misoprostol than previous analyses based on endoscopic data and modeling of all resource utilizations.
Idioma Inglês
Data de publicação 1998-01-01
Publicado em Arthritis and Rheumatism. Philadelphia: Lippincott Williams & Wilkins, v. 41, n. 1, p. 16-25, 1998.
ISSN 0004-3591 (Sherpa/Romeo, fator de impacto)
Publicador Lippincott Williams & Wilkins
Extensão 16-25
Fonte http://dx.doi.org/10.1002/1529-0131(199801)41:1<16
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000071418200003
Endereço permanente http://repositorio.unifesp.br/handle/11600/25837

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta